OGI — Organigram Global Inc.

Summary of Organigram (OGI) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Net Revenue: Increased 79% to $80.1 million from $44.7 million year-over-year.
• Full Year Fiscal 2025 Net Revenue: Rose 62% to $259.2 million from $159.8 million.
• Adjusted Gross Profit: Q4 saw an 85% increase to $30.6 million; full year adjusted gross profit reached $91 million, up from $53.9 million.
• Adjusted EBITDA: Q4 recorded $9.8 million, up 72% sequentially and 69% year-over-year; full year adjusted EBITDA was $21.9 million, a 160% increase from $8.4 million in 2024.
• Net Loss: Q4 net loss was $38 million, compared to a loss of $5.4 million in the prior year; full year net loss decreased 46% to $24.8 million.
• Cash Position: Total cash and short-term investments at year-end were $84.4 million, with $28.2 million unrestricted.

2. Strategic Updates and Business Highlights

• Market Position: Achieved #1 market share in Canada with 11.9% in fiscal 2025, with strong performances in key provinces.
• Acquisition of Motif Labs: Enhanced operational capabilities and distribution without market share dilution.
• International Expansion: Record international sales of $26.3 million, up 171% year-over-year, driven by partnerships in Germany and the U.S. market entry with hemp-derived THC beverages.
• Operational Improvements: Increased cultivation yields and capacity at the Moncton facility through advanced practices, contributing to record output.

3. Forward Guidance and Outlook

• Fiscal 2026 Expectations: Projecting net revenue growth to exceed $300 million, with continued improvements in adjusted gross margin and adjusted EBITDA.
• Free Cash Flow: Anticipated to be positive in fiscal 2026, with capital expenditures expected to be less than $10 million.
• Seasonal Trends: Expecting a strong Q1 but a seasonal sequential reduction compared to Q4.

4. Bad News, Challenges, or Points of Concern

• Temporary Market Share Impact: Experienced a decline in market share in Q1 due to an 8-week strike affecting distribution in British Columbia.
• Net Loss Increase: Significant year-over-year increase in net loss attributed to higher noncash mark-to-market adjustments.
• Regulatory Risks: Monitoring potential U.S. federal legislation that could impact hemp-derived THC products by November 2026.

5. Notable Q&A Insights

• International Growth: Management indicated that increased capacity (14,000 kg) is being realized, with disciplined approaches to supply expansion.
• Gross Margin Projections: Expected to improve beyond 35% in fiscal 2026, driven by operational efficiencies and synergies from the Motif acquisition.
• CapEx Plans: Anticipated to be significantly lower in fiscal 2026, focusing on sustaining capital rather than major expansions.

Overall, Organigram reported strong financial performance and strategic advancements in fiscal 2025, positioning itself for continued growth despite facing some regulatory and market challenges.